Ask about this productRelated genes to: ZIK1 Blocking Peptide
- Gene:
- ZIK1 NIH gene
- Name:
- zinc finger protein interacting with K protein 1
- Previous symbol:
- -
- Synonyms:
- ZNF762
- Chromosome:
- 19q13.43
- Locus Type:
- gene with protein product
- Date approved:
- 2006-08-11
- Date modifiied:
- 2014-11-19
Related products to: ZIK1 Blocking Peptide
Related articles to: ZIK1 Blocking Peptide
- Cervical cancer (CC) is a main malignancy affecting women globally, with a high mortality rate. Chemoradiotherapy resistance is a significant factor in determining treatment outcomes, and prognostic biomarkers are essential for the appropriate selection of therapeutic strategies. This study aimed to identify gene expression signatures that may allow for follow-up treatment response in CC patients. - Source: PubMed
de Melo Neto Angelo BorgesQueiroz Fábio Ribeirode Souza Melo Carolina PereiraDuarte Bruna Custódio DiasFerreira Jorge Gomes Goulartde Amorim Izabela Ferreira Gontijodo Amaral Laurence RodriguesBertarini Pedro Luiz Limade Figueiredo Franco Telma Maria Rosside Carvalho Andréa TeixeiraMartins-Filho Olindo Assisde Jesus Jeremias Wanderda Conceição Braga Letíciade Oliveira Salles Paulo Guilhermede Souza Gomes Matheus - The aim of the present study was to explore the association between N‑methyladenosine (m6A) modification regulatory gene‑related long noncoding (lnc)RNA RP1‑228H13.5 and cancer prognosis through bioinformatics analysis, as well as the impact of RP1‑228H13.5 on cell biology‑related behaviors and specific molecular mechanisms. Bioinformatics analysis was used to construct a risk model consisting of nine genes. This model can reflect the survival time and differentiation degree of cancer. Subsequently, a competing endogenous RNA network consisting of 3 m6A‑related lncRNAs, six microRNAs (miRs) and 201 mRNAs was constructed. A cell assay confirmed that RP1‑228H13.5 is significantly upregulated in liver cancer cells, which can promote liver cancer cell proliferation, migration and invasion, and inhibit liver cancer cell apoptosis. The specific molecular mechanism may be the regulation of the expression of zinc finger protein interacting with K protein 1 (ZIK1) by targeting the downstream hsa‑miR‑205. Further experiments found that the m6A methyltransferase 14, N‑adenosine‑methyltransferase subunit mediates the regulation of miR‑205‑5p expression by RP1‑228H13.5. m6A methylation regulatory factor‑related lncRNA has an important role in cancer. The targeting of hsa‑miR‑205 by RP1‑228H13.5 to regulate ZIK1 may serve as a potential mechanism in the occurrence and development of liver cancer. - Source: PubMed
Publication date: 2024/03/01
Xu JiaLiu ChangQu KaiZhang JingyaoLiu SinanMeng FandiWan Yong - Head and neck squamous cell carcinoma (HNSCC), a highly heterogeneous disease that involves multiple anatomic sites, is a leading cause of cancer-related mortality worldwide. Although the utility of noninvasive biomarkers based on circulating cell-free DNA (cfDNA) methylation profiling has been widely recognized, limited studies have been reported so far regarding the dynamics of cfDNA methylome in oral cavity squamous cell carcinoma (OCSCC). It is hypothesized in this study that comparison of methylation profiles in pre- and postsurgery plasma samples will reveal OCSCC-specific prognostic and diagnostic biomarkers. As a strategy to further prioritize tumor-specific targets, top differential methylated regions (DMRs) were called by reanalyzing methylation data from paired tumor and normal tissue collected in the the cancer genome atlas head-neck squamous cell carcinoma (TCGA) head and neck cancer cohort. Matched plasma samples from eight patients with OCSCC were collected at Moffitt Cancer Center before and after surgical resection. Plasma-derived cfDNA was analyzed by cfMBD-seq, which is a high-sensitive methylation profiling assay. Differential methylation analysis was then performed based on the matched samples profiled. In the top 200 HNSCC-specific DMRs detected based on the TCGA data set, a total of 23 regions reached significance in the plasma-based DMR test. The top five validated DMR regions (ranked by the significance in the plasma study) are located in the promoter regions of genes PENK, NXPH1, ZIK1, TBXT, and CDO1, respectively. The genome-wide cfDNA DMR analysis further highlighted candidate biomarkers located in genes SFRP4, SOX1, IRF4, and PCDH17. The prognostic relevance of candidate genes was confirmed by survival analysis using the TCGA data. This study supports the utility of cfDNA-based methylome profiling as a promising noninvasive biomarker source for OCSCC and HNSCC. - Source: PubMed
Publication date: 2023/01/13
Patel Krupal BPadhya Tapan AHuang JinyongHernandez-Prera Juan CLi TingyiChung Christine HWang LiangWang Xuefeng - Cervical squamous cell carcinoma (CESC) is a cancer with high mortality caused by human papillomavirus. The aim of this study was to uncover potential CESC biomarkers to help early diagnosis and treatment. - Source: PubMed
Liu MiaomiaoWei DongNie QianPeng LiliHe LiyaCui YujieYe Yuquan - MicroRNAs (miRNAs) serve an important regulatory role in carcinogenesis and cancer progression. Aberrant expression of miR-197-3p has been reported in various human malignancies. However, the role of miR-197-3p in the progression and prognosis of hepatocellular carcinoma (HCC) remains unknown. The present study demonstrated that miR-197-3p was downregulated in HCC tissues and that the low level of miR-197-3p expression in HCC tumours correlated with aggressive clinicopathological characteristics; thus, miR-197-3p may serve as a predictor for poor prognosis in patients with HCC. Additionally, miR-197-3p markedly inhibited the metastasis of HCC cells and . Bioinformatics analysis further identified zinc finger protein interacted with K protein 1 (ZIK1) as a novel target of miR-197-3p in HCC cells. These findings suggest that miR-197-3p may regulate the survival of HCC cells, partially through the downregulation of ZIK1. Therefore, the miR-197-3p/ZIK1 axis may serve as a novel therapeutic target in patients with HCC. - Source: PubMed
Publication date: 2018/12/18
Ni Jun-ShengZheng HaoHuang Zhi-PingHong Yong-GangOu Yang-LiuTao Yuan-PingWang Meng-ChaoWang Zhen-GuangYang YuanZhou Wei-Ping